Previous Close | 2.8900 |
Open | 2.8900 |
Bid | 2.5600 x 200 |
Ask | 2.6500 x 100 |
Day's Range | 2.5000 - 2.8900 |
52 Week Range | 0.7200 - 3.6900 |
Volume | |
Avg. Volume | 345,985 |
Market Cap | 104.332M |
Beta (5Y Monthly) | 1.33 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.1000 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.67 |
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be
Rezolute, Inc. ( NASDAQ:RZLT ) insiders who bought shares over the past year were rewarded handsomely last week. The...
Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) Effects of RZ358 on Ligand-Induced Insulin Receptor Activation in U2OS-INSRa Cells Effects of RZ358 on Ligand-Induced Insulin Receptor Activation in U2OS-INSRa Cells REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed t